You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • FRI0059 Routine Assessment of Patient Index Data 3 (RAPID3) – Defined Remission is as Stringent as ACR/Eular Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept

Share

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - prognosis, predictors and outcome
FRI0059 Routine Assessment of Patient Index Data 3 (RAPID3) – Defined Remission is as Stringent as ACR/Eular Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
FRI0059 Routine Assessment of Patient Index Data 3 (RAPID3) – Defined Remission is as Stringent as ACR/Eular Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept
(Your Name) has forwarded a page to you from Annals of the Rheumatic Diseases
(Your Name) thought you would like to see this page from the Annals of the Rheumatic Diseases web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.